Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Retained Earnings: 2022-2025

Historic Retained Earnings for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to -$1.1 billion.

  • Centessa Pharmaceuticals' Retained Earnings fell 27.66% to -$1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 billion, marking a year-over-year decrease of 27.66%. This contributed to the annual value of -$988.7 million for FY2024, which is 31.31% down from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Retained Earnings of -$1.1 billion as of Q3 2025, which was down 4.68% from -$1.1 billion recorded in Q2 2025.
  • Centessa Pharmaceuticals' Retained Earnings' 5-year high stood at -$440.2 million during Q1 2022, with a 5-year trough of -$1.1 billion in Q3 2025.
  • Its 3-year average for Retained Earnings is -$863.3 million, with a median of -$834.8 million in 2024.
  • Data for Centessa Pharmaceuticals' Retained Earnings shows a maximum YoY tumbled of 48.25% (in 2023) over the last 5 years.
  • Centessa Pharmaceuticals' Retained Earnings (Quarterly) stood at -$601.9 million in 2022, then declined by 25.10% to -$752.9 million in 2023, then crashed by 31.31% to -$988.7 million in 2024, then declined by 27.66% to -$1.1 billion in 2025.
  • Its last three reported values are -$1.1 billion in Q3 2025, -$1.1 billion for Q2 2025, and -$1.0 billion during Q1 2025.